Liu Han, Lv Zongwei, Zhang Gong, Wang Xia, Wang Yuan, Wang Kefeng
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Front Cell Dev Biol. 2023 May 2;11:1178221. doi: 10.3389/fcell.2023.1178221. eCollection 2023.
Gene editing tools using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-related systems have revolutionized our understanding of cancer. The purpose of this study was to determine the distribution, collaboration, and direction of cancer research using CRISPR. Data from the Web of Science (WoS) Core Collection database were collected from 4,408 cancer publications related to CRISPR from 1 January 2013to 31 December 2022. The obtained data were analyzed using VOSviewer software for citation, co-citation, co-authorship, and co-occurrence analysis. The number of annual publications has grown steadily over the past decade worldwide. The United States was shown, by far, to be the leading source of cancer publications, citations, and collaborations involving CRISPR than any other country, followed by China. Li Wei (Jilin University, China), and Harvard Medical School (Boston, MA, United States) were the author and institution with the most publications and active collaborations, respectively. The journal with the most contributions was ( = 147) and the journal with the most citations was ( = 12,111). The research direction of oncogenic molecules, mechanisms, and cancer-related gene editing was indicated based on keyword analysis. The current study has provided a comprehensive overview of cancer research highlights and future trends of CRISPR, combined with a review of CRISPR applications in cancer to summarize and predict research directions and provide guidance to researchers.
使用成簇规律间隔短回文重复序列(CRISPR)及相关系统的基因编辑工具彻底改变了我们对癌症的认识。本研究旨在确定使用CRISPR进行癌症研究的分布、合作情况及研究方向。从科学网(WoS)核心合集数据库收集了2013年1月1日至2022年12月31日期间与CRISPR相关的4408篇癌症出版物的数据。使用VOSviewer软件对所获数据进行引文、共被引、共同作者及共现分析。在过去十年中,全球年度出版物数量稳步增长。到目前为止,美国是涉及CRISPR的癌症出版物、引文及合作的主要来源国,领先于其他任何国家,其次是中国。来自中国吉林大学的李伟和美国马萨诸塞州波士顿的哈佛医学院分别是发表论文最多的作者和合作最活跃的机构。贡献最大的期刊是《 》( = 147),被引次数最多的期刊是《 》( = 12,111)。基于关键词分析表明了致癌分子、机制及癌症相关基因编辑的研究方向。本研究全面概述了癌症研究亮点及CRISPR的未来趋势,结合对CRISPR在癌症中应用的综述,总结并预测研究方向,为研究人员提供指导。